ESR1 and metastatic neoplasm: As CDK4/6 inhibitors represent standard-of-care therapeutics for patients with ERα-positive metastatic disease who relapsed after prior endocrine therapeutics [35], the phase of the disease in which ERα mutations are most apparent [36], we focused on ribociclib for downstream analyses on ERα-WT and ERα-MutA.